Blood transcript analysis and metastatic recurrent small bowel carcinoid management

Irvin M. Modlin; Ignat Drozdov; Lisa Bodei; Mark Kidd

doi:10.1186/1471-2407-14-564

Blood transcript analysis and metastatic recurrent small bowel carcinoid management

Irvin M. Modlin, Ignat Drozdov, Lisa Bodei, Mark Kidd

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA) measurement.Case presentation: We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index) to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan®, ¹¹C-5HTP-PET/CT and ⁶⁸Ga-DOTA-PET/CT in a patient with NET.Conclusions: Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests this parameter may also have utility as an index of therapeutic efficacy.

Original language	English
Article number	564
Journal	BMC Cancer
Volume	14
Issue number	1
DOIs	https://doi.org/10.1186/1471-2407-14-564
Publication status	Published - Aug 5 2014

Keywords

Gallium
Biomarker
Blood
Carcinoid
Chromogranin A
Gene marker
Neuroendocrine tumor
PCR
PET/CT

ASJC Scopus subject areas

Oncology
Cancer Research
Genetics
Medicine(all)

Access to Document

10.1186/1471-2407-14-564

Fingerprint Dive into the research topics of 'Blood transcript analysis and metastatic recurrent small bowel carcinoid management'. Together they form a unique fingerprint.

Cite this

@article{0de024eb99d24a77b4798ef89b25cef9,

title = "Blood transcript analysis and metastatic recurrent small bowel carcinoid management",

abstract = "Background: Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan{\textregistered}) and plasma Chromogranin A (CgA) measurement.Case presentation: We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index) to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan{\textregistered}, 11C-5HTP-PET/CT and 68Ga-DOTA-PET/CT in a patient with NET.Conclusions: Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests this parameter may also have utility as an index of therapeutic efficacy.",

keywords = "Gallium, Biomarker, Blood, Carcinoid, Chromogranin A, Gene marker, Neuroendocrine tumor, PCR, PET/CT",

author = "Modlin, {Irvin M.} and Ignat Drozdov and Lisa Bodei and Mark Kidd",

year = "2014",

month = aug,

day = "5",

doi = "10.1186/1471-2407-14-564",

language = "English",

volume = "14",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Blood transcript analysis and metastatic recurrent small bowel carcinoid management

AU - Modlin, Irvin M.

AU - Drozdov, Ignat

AU - Bodei, Lisa

AU - Kidd, Mark

PY - 2014/8/5

Y1 - 2014/8/5

N2 - Background: Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA) measurement.Case presentation: We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index) to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan®, 11C-5HTP-PET/CT and 68Ga-DOTA-PET/CT in a patient with NET.Conclusions: Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests this parameter may also have utility as an index of therapeutic efficacy.

AB - Background: Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA) measurement.Case presentation: We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index) to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan®, 11C-5HTP-PET/CT and 68Ga-DOTA-PET/CT in a patient with NET.Conclusions: Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests this parameter may also have utility as an index of therapeutic efficacy.

KW - Gallium

KW - Biomarker

KW - Blood

KW - Carcinoid

KW - Chromogranin A

KW - Gene marker

KW - Neuroendocrine tumor

KW - PCR

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=84906827234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906827234&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-14-564

DO - 10.1186/1471-2407-14-564

M3 - Article

C2 - 25095873

AN - SCOPUS:84906827234

VL - 14

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 564

ER -